-
The Central Commission for Discipline Inspection Announced: Falsified Health Checkups in Health Centers!
Time of Update: 2021-05-02
After understanding, this health center needs to collect more than 1,000 blood samples in just a few days because the inspection time is approaching, which is almost impossible to complete.
-
The Acting Director of the FDA talks about the Center of Excellence, the focus of the epidemic, and the accelerated approval review...
Time of Update: 2021-05-02
Woodcock said that because the new crown epidemic continues, it has put pressure on FDA staff and increased the workload, so it is not suitable for implementing structural reforms within the agency.
-
totally relaxed!
Time of Update: 2021-05-02
[1] Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13.
Retrieved April 9, 2021, from -announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13 /
Retrieved April 9, 2021, from -announces-presentation-at-aacr-highlighting-initial-data-from-phase-1-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13 /
-
Pharmacies in Shanxi Province resume sales of antipyretic drugs
Time of Update: 2021-05-02
According to the "Notice on Strictly Implementing the Requirements for Suspending the Sale of Antipyretic Drugs During the Period of Epidemic Prevention and Control" issued by the Shanxi Provincial Food and Drug Administration at the beginning of this year, retail pharmacies should immediately suspend the sale of antipyretic drugs to the public after receiving the notice, and make an inventory.
-
Baolight intends to spend 11.7 million yuan to set up a joint venture to develop
Time of Update: 2021-05-02
On April 19, Bolaite issued an announcement that, based on strategic planning and business development needs, in order to expand the blood purification market, the company plans to jointly fund and establish a holding subsidiary Sichuan Bolaite Zhili Medical Technology Co.
00% of the registered capital of the joint venture company; Zhili Medical invested RMB 6.
-
Medical Talent Recruitment (04.09 update)
Time of Update: 2021-05-02
Job recruitment requirements: ① More than two years of sales experience, foreign company experience is preferred; ② Growth thinking, with the ability to quickly adapt to new changes and learn new knowledge; ③ Strong resistance to pressure, strong self-driving force, and always maintain a positive attitude to break through difficulties .
-
NEJM released two studies for the first time revealing the potential for thrombosis after new crown vaccination...
Time of Update: 2021-05-02
In the second study, the German research team analyzed the clinical and blood test data of 11 patients who experienced thrombosis or thrombocytopenia after being vaccinated with the ChAdOx1 nCov-19 new crown vaccine in Germany and Austria.
-
Summary of U.S. oral drug recalls in 2020
Time of Update: 2021-05-02
Also in May 2020, when the FDA detected a batch of products with NDMA content above the acceptable limit, Apotex voluntarily recalled its metformin hydrochloride extended-release tablets 500 mg.
-
An article to understand the pathological and epidemiological characteristics of DLBCL
Time of Update: 2021-04-28
These cases are now classified as "high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements", are commonly referred to as double or triple-hit lymphomas, and are associated with poor prognosis for R-CHOP treatment.
-
One step closer to listing! Innovative T cell immunotherapy releases clinical data analysis丨Yi Mai Meng broke the news
Time of Update: 2021-04-28
Recommended reading: Atara's unique immune cell therapy enters Phase III clinical trials, and is expected to become the first "off-the-shelf" T cell product approved for marketing Yimaihei Technology tab-cel® is currently under Atara's research and development progress The fastest T cell immunotherapy; in addition to EBV+PTLD patients after transplantation who failed rituximab treatment, it is also planned to be used for other EBV-related hematomas and solid tumors including nasopharyngeal carcinoma.
-
Understand NEJM in 2 minutes: pegcetacoplan treats paroxysmal nocturnal hemoglobinuria
Time of Update: 2021-04-28
[Editor's note] NEJM Quick Take introduces an article of the latest NEJM in 2 minutes in the form of animation. "NEJM Frontiers of Medicine" updates the video summary of the current NEJM treatises e
-
2021 EBMT | Allo-HCT followed by bortezomib in the treatment of MM can significantly reduce the incidence of moderate/severe cGVHD
Time of Update: 2021-04-28
hypothesized that the use of bortezomib (BTZ) maintenance therapy after allo-HCT could reduce the recurrence rate and the incidence of cGVHD in high-risk, young MM patients, and conducted clinical studies to try to determine the effect of bone marrow measurable residual disease (MRD) The impact of future disease progression.
-
Blocking interleukin-22 can reduce stress-induced anemia in mice | "Nature-Immunology" paper
Time of Update: 2021-04-28
Laurie Glimcher and colleagues at the Dana-Farber Cancer Institute in Boston, Massachusetts, USA, and colleagues identified a stress-induced feature that can lead to a decrease in red blood cells in mice with abnormal expression of Riok2-the human Riok2 gene is derived from chromosome 5.
-
When "Vernal Equinox" Meets "Platelet Day" | Professor Fang Jianpei Talks about Children's ITP Management
Time of Update: 2021-04-28
Although childhood ITP is a benign self-limiting disease, 80% of cases can return to normal platelet counts within 12 months after diagnosis, but there are still about 20% of children whose disease course lasts for more than 1 year.
-
2021 EBMT | TBF program can improve disease-free survival of AML patients in complete remission
Time of Update: 2021-04-28
2020), cytepa + busulfan + fludarabine (TBF) The pretreatment program can reduce the risk of recurrence in patients with acute myeloid leukemia (AML) in the first and second remission (CR1/CR2) stages.
-
2021 EBMT | ASCT sequential allo-HSCT followed by maintenance treatment can improve the efficacy of MM patients?
Time of Update: 2021-04-28
Nicolaus Kröger and others in Germany conducted a study comparing autologous hematopoietic stem cell transplantation (ASCT) sequential allo-HSCT (auto-allo TSCT) followed by maintenance therapy, and ASCT sequential ASCT (auto-auto TSCT) followed In order to maintain the efficacy of treatment in newly diagnosed MM patients, the results of the study will be announced at the 47th European Association of Blood and Bone Marrow Transplantation (EBMT 2021) in 2021.
-
2021 EBMT｜Axi-cel speaks with real-world data and treats R/R LBCL ORR up to 78%
Time of Update: 2021-04-28
The cytokine release syndrome (CRS) and immune effector cell-related neurotoxic syndrome (ICANS) were graded according to the ASTCT consensus standard, and the remission was assessed according to the Lugano standard.
The median time from approval to infusion was 54 days.
The median time from leukocyte separation to infusion was 39 days.
-
Can low-risk MDS benefit from oral azacitidine?
Time of Update: 2021-04-24
Professor Guillermo Garcia-Manero and others recently reported the results of a randomized, placebo-controlled, phase III clinical study that evaluated placebo vs CC-486 (oral azacitidine) in patients with red blood cell transfusion dependence ( RBC-TD) anemia and thrombocytopenia, and the efficacy and safety of low-risk myelodysplastic syndrome (LR-MDS) patients determined by the International Prognostic Scoring System (IPSS).
-
Exploring the optimal treatment strategy for the subgroup with good prognosis in standard-risk children with B-ALL
Time of Update: 2021-04-24
The clinical trial of AALL0331 is mainly to determine whether pegaspargase intensive therapy can further improve standard risk (SR) subgroup B-cell acute lymphoblastic leukemia with good prognostic characteristics compared with standard pediatric oncology group (COG) low-intensity therapy (B-ALL) The rate of continuous complete remission (CCR) in children.
-
Professor Lu Bingbing: Diagnosis and treatment of patients with hematopoietic stem cell transplantation complicated with bronchiolitis obliterans syndrome (BOS)
Time of Update: 2021-04-24
At the meeting, Professor Lu Bingbing from the Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, gave a wonderful sharing on "Diagnosis and Treatment of Bronchiolitis Obliterans Syndrome (BOS) in Patients with Hematopoietic Stem Cell Transplantation".
